Preview

Атеротромбоз

Расширенный поиск

РОЛЬ ОПРЕДЕЛЕНИЯ ФУНКЦИОНАЛЬНОЙ АКТИВНОСТИ ТРОМБОЦИТОВ ПРИ ПРИМЕНЕНИИ КЛОПИДОГРЕЛА В ПРАКТИКЕ ЛЕЧЕНИЯ БОЛЬНЫХ С КОРОНАРНОЙ БОЛЕЗНЬЮ СЕРДЦА

https://doi.org/10.21518/2307-1109-2014-1-22-32

Полный текст:

Аннотация

.

Об авторе

И. С. Явелов
ФГБУН «НИИ физико-химической медицины» ФМБА России, г. Москва
Россия
д.м.н., ведущий научный сотрудник


Список литературы

1. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome – Fact and fiction. Thromb Haemost, 2011, 106: 191-202.

2. Breet NJ, van Werkum JW, Bouman HJ et al. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA, 2010, 303: 754-762.

3. Tantry US, Bonello L, Aradi D et al., for the Working Group on On-Treatment Platelet Reactivity. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. JACC, 2013, 62: 2261-2273.

4. Aradi D, Storey RF, Komocsi A et al., on behalf of the Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J, 2013. doi:10.1093/eurheartj/eht375.

5. Kirtane AJ, Rinaldi M, Parise H et al. Impact of point-of-care platelet function testing among patients with and without acute coronary syndromes undergoing PCI with drug-eluting stents: an ADAPTDES substudy. JACC, 2012, 59: E291.

6. Stone GW, Witzenbichler B, Weisz G et al., for the ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 2013, 382: 614-623.

7. Reny J-L, Berdague P, Poncet A et al., for the Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group. Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients. Results of the Antiplatelet Drug Resistances and Ischemic Events Study. Circulation, 2012, 125: 3201-3210.

8. Gurbel PA, Erlinge D, Ohman EM et al., for the TRILOGY ACS Platelet Function Substudy Investigators. Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. The TRILOGY ACS Platelet Function Substudy. JAMA, 2012, 308: 1785-1794.

9. Price MJ, Berger PB, Teirstein PS et al., for the GRAVITAS Investigators. Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. The GRAVITAS Randomized Trial. JAMA, 2011, 305: 1097-1105.

10. Price MJ, Angiolillo DJ, Teirstein PS et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. A Time- Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. Circulation, 2011, 124: 1132-1137.

11. Trenk D, Stone GW, Gawaz M et al. A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. JACC, 2012, 59: 2159-2164.

12. Collet J-P, Cuisset T, Rangé G et al., for the ARCTIC Investigators. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. N Engl J Med, 2012. DOI: 10.1056/NEJMoa1209979.

13. Cassese S, Byrne RA, Tada T et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J, 2012, 33: 3078-3087.

14. Kim B-K, Hong M-K, Shin D-H, for the RESET Investigators. New Strategy for Discontinuation of Dual Antiplatelet Therapy. The RESET Trial (Real Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). JACC, 2012, 60: 1340-1348.

15. Valgimigli M, Campo G, Monti M et al. Short- Versus Long-term Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Randomized Multicentre Trial. Circulation, 2012. doi: CIRCULATIONAHA.111.071589.

16. Valgimigli M, Borghesi M, Tebaldi M et al., for the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Eur Heart Journal, 2013, 34: 909-919.

17. Feres F, Costa RA, Abizaid A et al., for the OPTIMIZE Trial Investigators. Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents The OPTIMIZE Randomized Trial. JAMA, 2013. doi:10.1001/jama.2013.282183.

18. Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet, 2012, 379: 1393-1402.

19. Silber S, Windecker S, Vranckx P, Serruys PW, on behalf of the RESOLUTE All Comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet, 2011, 377: 1241-1247.

20. No Stent Thrombosis Seen When Plavix and Aspirin Stopped Early New Analysis of Medtronic’s 5,000 Patient RESOLUTE Drug-Eluting Stent Clinical Program Shows No Increased Risk with Premature Cessation of Dual Antiplatelet Therapy. http://www.ptca.org/ news/2013/0314_MEDTRONIC_RESOLUTE.html.

21. Aradi D, Tornyos A, Pintér T et al. Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing Impact of Prasugrel and High-Dose Clopidogrel. JACC, 2014, 63: 1061-1070.

22. Aradi D, Komуcsi A, Price MJ, et al., on behalf of the Tailored Antiplatelet Treatment Study Collaboration. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol, 2012. doi: 10.1016/j.ijcard.2012.05.100

23. Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial (TROPICAL-ACS). Описание доступно на сайте http://clinicaltrials.gov/ct2/show/ NCT01959451.

24. Mehran R, Rao SV, Bhatt DL et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials. A Consensus Report From the Bleeding Academic Research Consortium. Circulation, 2011, 123: 2736-2747.

25. Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel (ANTARCTIC). Описание доступно на сайте http://clinicaltrials.gov/show/NCT01538446

26. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J, 2010, 31: 2501-2555.

27. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2011. doi:10.1093/eurheartj/ehr236.

28. ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J, 2012. doi:10.1093/eurheartj/ehs215.

29. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. JACC, 2011. doi:10.1016/j. jacc.2011.08.007.

30. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation, 2013, 127. DOI: 10.1161/ IR.0b013e31828478ac.

31. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC, 2013, 61. doi:10.1016/j.jacc.2012.11.019.


Для цитирования:


Явелов И.С. РОЛЬ ОПРЕДЕЛЕНИЯ ФУНКЦИОНАЛЬНОЙ АКТИВНОСТИ ТРОМБОЦИТОВ ПРИ ПРИМЕНЕНИИ КЛОПИДОГРЕЛА В ПРАКТИКЕ ЛЕЧЕНИЯ БОЛЬНЫХ С КОРОНАРНОЙ БОЛЕЗНЬЮ СЕРДЦА. Атеротромбоз. 2014;(1):22-32. https://doi.org/10.21518/2307-1109-2014-1-22-32

For citation:


Явелов И.С. . Atherothrombosis. 2014;(1):22-32. (In Russ.) https://doi.org/10.21518/2307-1109-2014-1-22-32

Просмотров: 298


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)